Clinton "Lied" About GOP Medicare Plans

12 May 1996

US House Speaker Newt Gingrich has said that President Clinton lied to elderly Americans about the character of Republican Medicare reforms in order to boost his own reelection campaign, adding that Pres Clinton's tactics in 1995 during a debate over Medicare will be part of a GOP campaign offensive this year.

A campaign of "disinformation" frightened 37 million seniors by saying the GOP plan would produce deep spending cuts, he said. The plan included a growth limit that Mr Gingrich said would have still allowed spending up to $7,300 a year for each senior in seven years, from $4,800 at present. That would have slowed Medicare spending by about $170 billion in the period, down from the original plan for $270 billion lower spending.

Medicare began to lose money in 1995 and the Medicare Part A hospital trust fund can now be expected to go bankrupt in 2001, a year earlier than projected by the plan's trustees up to now, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight